Carl June, MD, Professor in the Perelman School of Medicine and member of the Penn Bioengineering Graduate Group, was quoted in a recent press release announcing a new international partnership between Penn Medicine (PSOM), the Children’s Hospital of Pennsylvania (CHOP), and Costa Rica’s CCSS, or the Caja Costarricense de Seguro Social (Social Security Program), to develop CAR T research in Costa Rica. June is a world renowned cancer cell therapy pioneer whose research led to the initial development and FDA approval of CAR T cell therapy:
“‘At least 15,000 patients across the world have received CAR T cells, and dozens more clinical trials using this approach are in progress, for almost every major tumor type, but people in many parts of the globe still do not have access to treatment with these transformative therapies,’ said Carl H. June, MD, the Richard W. Vague Professor in Immunotherapy and director of the Center for Cellular Immunotherapies in Penn’s Perelman School of Medicine. “We are honored to work with our colleagues in Costa Rica in hopes of building a path for patients in underserved areas to have the opportunity to benefit from clinical research programs offering this personalized therapy.’”
Yale E. Cohen, Professor of Otorhinolaryngology, with secondary appointments in Neurscience and Bioengineering, was appointed Assistant Dean of Research Facilities and Resources at the Perelman School of Medicine at the University of Pennsylvania, effective April 1, 2022. Cohen is currently Chair of the Penn Bioengineering Graduate Group, and Director of the Hearing Sciences Center:
“Many of you are already quite familiar with Dr. Cohen, as his leadership roles in research training and education at PSOM and the University are far-reaching and impactful. Dr. Cohen is a Professor of Otorhinolaryngology with secondary appointments in the Department of Neuroscience and Engineering’s Department of Bioengineering. Recognized widely for his deep commitment to our teaching and training community, Dr. Cohen chairs the Bioengineering Graduate Group, and in 2020 received the prestigious Jane M. Glick Graduate Student Teaching Award, which honors clinicians and scientists who exemplify outstanding quality of patient care, mentoring, research, and teaching.”
Kevin B. Johnson, David L. Cohen University Professor in Biostatistics, Epidemiology and Informatics and in Computer and Information Science, has been elected to the 2022 Class of the American Institute for Medical and Biological Engineering (AIMBE) Fellows. Johnson joined the Penn faculty in 2021. He also holds secondary appointments in Bioengineering, in Pediatrics, and in the Annenberg School for Communication, and is the Vice President for Applied Informatics for the University of Pennsylvania Health System.
Election to the AIMBE College of Fellows is among the highest professional distinctions accorded to a medical and biological engineer. College membership honors those who have made outstanding contributions to “engineering and medicine research, practice, or education” and to “the pioneering of new and developing fields of technology, making major advancements in traditional fields of medical and biological engineering, or developing/implementing innovative approaches to bioengineering education.”
Johnson was nominated, reviewed, and elected by peers and members of the AIMBE College of Fellows for his pioneering discoveries in clinical informatics, leading to advances in data acquisition, medication management, and information aggregation in medical settings.
A formal induction ceremony was held during AIMBE’s 2022 Annual Event on March 25, 2022. Johnson was inducted along with 152 colleagues who make up the AIMBE Fellow Class of 2022. For more information about the AIMBE Annual Event, please visit www.aimbe.org.
Read Johnson’s AIMBE election press release here. Find the full list of 2022 Fellows here.
Cells in complex organisms undergo frequent changes, and researchers have struggled to monitor these changes and create a comprehensive profile for living cells and tissues. Historically researchers have been limited to only 3-5 markers due to spectral overlaps in fluorescence microscopy, an essential tool required for imaging cells. With only this small handful of markers, it is difficult to monitor protein expressions of live cells and a comprehensive profile of cellular dynamics cannot be created. However, a new study in Nature Biotechnology addresses these limitations by demonstrating a new method for comprehensive profiling of living cells.
Jina Ko, Assistant Professor in Bioengineering in the School of Engineering and Applied Science and in Pathology and Laboratory Medicine in the Perelman School of Medicine, served as lead author of this new study. Ko conducted postdoctoral research at Massachusetts General Hospital (MGH) and the Wyss Institute at Harvard University, and the work for this study was done in collaboration with Jonathan Carlson M.D., Ph.D. and Ralph Weissleder M.D., Ph.D. of MGH. Ko’s lab at Penn develops novel technologies using bioengineering, molecular biology, and chemistry to address diagnostic challenges for precision medicine.
To address these limitations in microscopy, Ko’s team developed a new chemistry tool which was highly gentle to cells. This “scission-accelerated fluorophore exchange (or SAFE)” method utilizes “click” chemistry, a type of chemistry that follows examples found in nature to create fast and simple reactions. This new SAFE method enabled Ko to achieve non-toxic conditions to living cells and tissues, whereas previous methods have used harsh chemicals that would strip off fluorophores and consequently would not work with living cells and tissues.
With the development of SAFE, the authors demonstrated that researchers can now effectively perform multiple cycles of cell profiling and can monitor cellular changes over the course of their observations. Instead of the previous limitation of 3-5 markers total, SAFE allows for many more cycles and can keep track of almost as many markers as the researcher wants. One can now stain cells and quench/release fluorophores and repeat the cycle multiple times for multiplexing on living cells. Each cycle can profile 3 markers, and so someone interested in profiling 15 markers could easily perform 5 cycles to achieve this much more comprehensive cell profile. With this breakthrough in more detailed imaging of cells, SAFE demonstrates broad applicability for allowing researchers to better investigate the physiologic dynamics in living systems.
The U.S. Food and Drug Administration has expanded its approval for Kymriah, a personalized cellular therapy developed at the Abramson Cancer Center, this time for the treatment of adults with relapsed/refractory follicular lymphoma who have received at least two lines of systemic therapy. “Patients with follicular lymphoma who relapse or don’t respond to treatment have a poor prognosis and may face a series of treatment options without a meaningful, lasting response,” said Stephen J. Schuster, the Robert and Margarita Louis-Dreyfus Professor in Chronic Lymphocytic Leukemia and Lymphoma in the Division of Hematology Oncology. It’s the third FDAapproval for the “living drug,” which was the first of its kind to be approved, in 2017, and remains the only CAR T cell therapy approved for both adult and pediatric patients.
“In just over a decade, we have moved from treating the very first patients with CAR T cell therapy and seeing them live healthy lives beyond cancer to having three FDA-approved uses of these living drugs which have helped thousands of patients across the globe,” said Carl June, MD, the Richard W. Vague Professor in Immunotherapy in the department of Pathology and Laboratory Medicine in Penn’s Perelman School of Medicine and director of the Center for Cellular Immunotherapies in the Abramson Cancer Center and director of the Parker Institute for Cancer Immunotherapy at Penn. “Today’s news is new fuel for our work to define the future of cell therapy and set new standards in harnessing the immune system to treat cancer.”
Research from June, a member of the Penn Bioengineering Graduate Group, led to the initial FDA approval for the CAR T therapy (sold by Novartis as Kymriah) for treating acute lymphoblastic leukemia (ALL), one of the most common childhood cancers.
César de la Fuente, Presidential Assistant Professor in Psychiatry, Bioengineering, Microbiology, and in Chemical and Biomolecular Engineering has been honored with a 2022 Young Investigator Award by the Royal Spanish Society of Chemistry (RSEQ) for his pioneering research efforts to combine the power of machines and biology to help prevent, detect, and treat infectious diseases.
In an interview with Quanta Magazine, Vijay Balasubramanian discusses his work as a theoretical physicist, noting his study of the foundations of physics and the fundamentals of space and time. He speaks of the importance of interdisciplinary study and about how literature and the humanities can contextualize scientific exploration in the study of physics, computer science, and neuroscience.
Balasubramanian is Cathy and Marc Lasry Professor in the Department of Physics and Astronomy in the Penn School of Arts and Sciences and a member of the Penn Bioengineering Graduate Group.
Kevin B. Johnson, M.D., M.S., was featured in Cincinnati Children’s Hospital’s “Envisioning Our Future for Children” speaker series, discussing “the evolution of the EHR and its future directions.” An electronic health record, or EHR, is a digital record of a patient’s chart, recording health information and data, coordinating orders, tracking results, and providing patient support. Johnson “predicts a new wave of transformation in digital health technologies that could make rapid progress” in several areas of medicine, including reducing cost and improving patience outcomes. Johnson is Vice President for Applied Informatics at the University of Pennsylvania Health System and the David L. Cohen University Professor with appointments in Biostatistics, Epidemiology and Informatics and Computer and Information Science and secondary appointments in the Annenberg School for Communication, Pediatrics, and Bioengineering.
Penn Bioengineering alumnus Jackson Foster (BSE 2014) was included in the Los Angeles Business Journal’s 2021 “20 in Their 20s” list, recognizing rising entrepreneurial stars of L.A.’s business community. Foster is the Founder and Chief Executive of the San Francisco-based Edily Learning, an education technology company which has created an app focused on education, learning goals, and personalized content using a TikTok-like algorithm.
Susan Margulies, Professor Emeritus in Bioengineering, has been selected to lead the National Science Foundation’s (NSF) Directorate of Engineering, “the first biomedical engineer to head the directorate.” Margulies is chair of the Wallace H. Coulter Department of Biomedical Engineering at the Georgia Institute of Technology and Emory University. She earned her master’s and doctoral degrees from Penn Bioengineering before joining the department as an Assistant Professor in 1993.
In a press release from Emory University, Margulies stated that, “The opportunity to serve the NSF resonates with my values — catalyzing impact through innovation, rigor, partnership, and inclusion.” The announcement continues:
“Building on initiatives she developed at the University of Pennsylvania, Margulies prioritized career development for faculty and Ph.D. graduates during her years leading Coulter BME. She added dedicated staff to help doctoral students prepare for increasingly popular career paths outside of academia. The department increased the diversity of Ph.D. students and improved faculty diversity at all ranks during her tenure. Margulies oversaw hiring of 20 new faculty members and launched formalized mentoring for early career professors, including creating a new associate chair position dedicated to faculty development.”
Margulies will step down from her position as chair in Coulter BME though she will remain in the Georgia Tech and Emory faculty. Her Injury Biomechanics Lab studies “the influence of mechanical factors on the structure and function of human tissues from the macroscopic to microscopic level, with an emphasis on the brain and lungs.”